Skip to Main Content

Author Details

Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2001
60
22
PMIDPaper TitleJournal TitlePublished Year
36057651Clinical management and outcomes of HIV-positive patients newly diagnosed with prostate cancer: a single institution experience.Prostate Cancer Prostatic Dis2024
36367998Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.J Clin Oncol2023
37971875MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression.JCI Insight2023
37211963Test-retest repeatability of organ uptake on PSMA-targeted <sup>18</sup> F-DCFPyL PET/CT in patients with prostate cancer.Prostate2023
37148233Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.J Neurosurg Spine2023
37307876Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images.Mod Pathol2023
37471632Vascular Expression of Prostate-specific Membrane Antigen (PSMA) in MiTF Family Translocation Renal Cell Carcinoma and Related Neoplasms.Appl Immunohistochem Mol Morphol2023
37027449Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.Oncologist2023
36857796Role of bromodomain and extraterminal (BET) proteins in prostate cancer.Expert Opin Investig Drugs2023
36857019Multi-timepoint imaging with PSMA-targeted [<sup>18</sup>F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging.Ann Nucl Med2023
36865273MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression.bioRxiv2023
36632656Lack of repeatability of radiomic features derived from PET scans: Results from a <sup>18</sup> F-DCFPyL test-retest cohort.Prostate2023
36628897Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer.Eur J Cancer2023
34326128The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.J Nucl Med2022
35677016Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss.Eur Urol Open Sci2022
35416959A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent.Clin Cancer Res2022
35357024Bipolar androgen therapy (BAT): A patient's guide.Prostate2022
36064785The shifting treatment paradigm of metastatic renal cell carcinoma.Nat Rev Urol2022
36194476Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC.J Clin Invest2022
35283693High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with <sup>18</sup>F-DCFPyL.Mol Imaging2022
34538582Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy.Clin Genitourin Cancer2022
32624280A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.Eur Urol2021
33617303TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.J Clin Oncol2021
33864855Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes.Urology2021
33608426Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide.J Nucl Med2021
34645612Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer.Cancer Res2021
34007013The interplay of microbiota and hormone regulation in men with prostate cancer.Prostate Cancer Prostatic Dis2021
34003011Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.J Urol2021
33452039Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.J Nucl Med2021
33419682The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.Eur Urol2021
33383350Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.Eur J Cancer2021
31176623Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.Eur Urol2020
32870734<i>BRCA1</i> Versus <i>BRCA2</i> and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?J Clin Oncol2020
32250727Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on <sup>18</sup>F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer.J Urol2020
32494029Advanced renal cell carcinoma and COVID-19 - a personal perspective.Nat Rev Urol2020
32487038A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).BMC Cancer2020
30293905Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.Eur Urol2019
31650100Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy.JCO Precis Oncol2019
32328561Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.JNCI Cancer Spectr2019
30218388Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [<sup>18</sup>F]DCFPyL PET/CT.Mol Imaging Biol2019
31530439PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.Clin Genitourin Cancer2019
31196032A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).BMC Cancer2019
31419509Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.Int J Radiat Oncol Biol Phys2019
31147927Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted <sup>18</sup>F-DCFPyL PET/CT.Ann Nucl Med2019
30655087The Microbiome and Genitourinary Cancer: A Collaborative Review.Eur Urol2019
29368341Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.Prostate2018
29988102Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies.Prostate Cancer Prostatic Dis2018
29854870Germline genetic testing in prostate cancer - further enrichment in variant histologies?Oncoscience2018
29851094Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate.Prostate2018
27720577Early use of chemotherapy in metastatic prostate cancer.Cancer Treat Rev2017
  • 1 - 50 of 60

Recommended Authors

Himisha Beltran
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 24
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 3
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 6
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 14
Gerhardt Attard
The Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 27
Niven Mehra
Radboud university medical center
Career Start Year 2004
Number of shared co-authors 12
Rahul Aggarwal
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 13
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Career Start Year 2003
Number of shared co-authors 13
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 6
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 2002
Number of shared co-authors 16
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 10
Kim N Chi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 17
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 14
Michael J Morris
Memorial Sloan Kettering Cancer Center
Career Start Year 1999
Number of shared co-authors 16
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1997
Number of shared co-authors 19
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Career Start Year 1997
Number of shared co-authors 14
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 8
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 10
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 11
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 18
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 14
Neil E Fleshner
University of Toronto
Career Start Year 1989
Number of shared co-authors 14
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 14
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1987
Number of shared co-authors 15
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 18
Eric J Small
University of California san francisco
Career Start Year 1985
Number of shared co-authors 23
Maha Hussain
Northwestern University
Career Start Year 1984
Number of shared co-authors 18
Eric A Klein
Cleveland Clinic
Career Start Year 1984
Number of shared co-authors 25
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 21
Howard I Scher
Memorial Sloan Kettering Cancer Center
Career Start Year 1973
Number of shared co-authors 19

Collaborators

Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 33
Mario A Eisenberger
Johns Hopkins University
Co-authored papers 23
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Co-authored papers 16
Michael A Carducci
Johns Hopkins School of Medicine
Co-authored papers 15
Channing J Paller
Johns Hopkins University School of Medicine
Co-authored papers 12
Tamara L Lotan
Johns Hopkins University School of Medicine
Co-authored papers 6
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Co-authored papers 6
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 6
Matthew P Deek
Rutgers Robert Wood Johnson Medical School, Rutgers University
Co-authored papers 5
Theodore L DeWeese
Johns Hopkins University School of Medicine
Co-authored papers 5
Danny Y Song
Johns Hopkins University School of Medicine
Co-authored papers 5
Ryan Phillips
Johns Hopkins University
Co-authored papers 4
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Co-authored papers 4
Phillip M Pierorazio
Co-authored papers 4
Stephen Greco
Johns Hopkins University School of Medicine
Co-authored papers 4
Curtiland Deville
Johns Hopkins University
Co-authored papers 4
Bruce J Trock
Johns Hopkins University School of Medicine
Co-authored papers 3
Neil B Desai
University of Texas Southwestern Medical Center
Co-authored papers 3
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Co-authored papers 2
William B Isaacs
The Brady Urological Institute, The Johns Hopkins School of Medicine
Co-authored papers 2
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 2
Yongmei Chen
Co-authored papers 2
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 2
David G McLeod
Co-authored papers 1
Piet Ost
Ghent University, GZA Ziekenhuizen
Co-authored papers 1
Oliver Sartor
Tulane University School of Medicine
Co-authored papers 1
Urban Emmenegger
Odette Cancer Centre
Co-authored papers 1
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Co-authored papers 1
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Co-authored papers 1
Release 1.2